Big Pharma Approvals — April 24, 2026

Merck Sharp and Dohme LLC received FDA NME approval for Doravirine and Islatravir (Idvynso™), a high-strength bullish signal (8/10 strength, 8/10 materiality) indicating new molecular entity launch potential and sponsor execution capability.

Regeneron Pharmaceuticals secured label expansion approval for Dupilumab (Dupixent), a moderate bullish signal (5/10 strength, 5/10 materiality) that extends its market reach without disclosed commercial details.

Merck Sharp and Dohme LLC's Doravirine and Islatravir (Idvynso™) NME approval opens near-term commercialization in its therapeutic class.

Regeneron Pharmaceuticals' Dupilumab (Dupixent) label expansion supports medium-term franchise growth.

Two bullish approvals from major sponsors underscore Big Pharma's consistent FDA success in label expansions and NMEs, even under 'other' categorization.

{"entity"=>"DORAVIRINE AND ISLATRAVIR (MERCK SHARP AND DOHME LLC)", "reason"=>"High-conviction NME approval requires tracking of undisclosed market position and peak sales potential.", "trigger"=>"commercial launch date, initial sales readout"}

{"entity"=>"DUPILUMAB (REGENERON PHARMACEUTICALS)", "reason"=>"Label expansion approval with moderate signal strength; monitor for franchise revenue contribution.", "trigger"=>"payer coverage decisions, Q2 earnings update"}